acetohydroxamic acid (Rx)

Brand and Other Names:Lithostat
  • Print

Dosing & Uses

AdultPediatricGeriatric

Dosage Forms & Strengths

tablet

  • 250mg

Chronic Urinary Tract Infection

Indicated for chronic UTS caused by urea-splitting organisms

Initial: 12 mg/kg/day PO divided q6 -8hr on empty stomach  

Maintenance: 250 mg PO q6-8hr; not to exceed 1.5 g/day

Renal Impairment

SCr 1.8-2.5 mg/dL [159-221 micromoles/L]: Dose q12hr; not to exceed 1 g/day

SCr >2.5 mg/dL [>221 micromoles/L]: Not recommended

Dosage Forms & Strengths

tablet

  • 250mg

Chronic Urinary Tract Infection

Indicated for chronic UTS caused by urea-splitting organisms

Initial: 10 mg/kg/day PO divided q6-8hr on empty stomach; titrate to patient response  

Chronic Urinary Tract Infection

Indicated for chronic UTS caused by urea-splitting organisms

Initial: 12 mg/kg/day PO divided q6-8hr on empty stomach

Maintenance: 250 mg PO q6-8hr; not to exceed 1.5 g/day

Next:

Interactions

Interaction Checker

and acetohydroxamic acid

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (0)

                Monitor Closely (1)

                • sodium picosulfate/magnesium oxide/anhydrous citric acid

                  acetohydroxamic acid decreases effects of sodium picosulfate/magnesium oxide/anhydrous citric acid by altering metabolism. Use Caution/Monitor. Coadministration with antibiotics decreases efficacy by altering colonic bacterial flora needed to convert sodium picosulfate to active drug.

                Minor (6)

                • ethanol

                  acetohydroxamic acid, ethanol. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Temporary rash, flushing.

                • ferric maltol

                  acetohydroxamic acid decreases levels of ferric maltol by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • ferrous fumarate

                  acetohydroxamic acid decreases levels of ferrous fumarate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • ferrous gluconate

                  acetohydroxamic acid decreases levels of ferrous gluconate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • ferrous sulfate

                  acetohydroxamic acid decreases levels of ferrous sulfate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • rose hips

                  acetohydroxamic acid decreases levels of rose hips by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                Previous
                Next:

                Adverse Effects

                >10%

                Mild headache; first 48 hours (30%)

                Anorexia (20-25%)

                Malaise (20-25%)

                Nausea (20-25%)

                Vomiting (20-25%)

                Anxiety (20%)

                Confused (20%)

                Depression (20%)

                Involuntary quivering (20%)

                Hemolytic anemia (15%)

                <1%

                Alopecia

                Blood clot

                Macular rash

                Phlebitis

                Previous
                Next:

                Warnings

                Contraindications

                Hypersensitivity

                Pts. amenable to definitive surgery & antimicrobial agents, infection by non-urease producing organisms, urinary infections controlled by culture-specific antimicrobials, severe renal impairment (CrCl <20 mL/min &/or serum creatinine>2.5 mg/dL [221 umol/L]), inadequate contraception (females), pregnancy

                Cautions

                Always use with appropriate antimicrobial treatment

                Potential teratogen

                Previous
                Next:

                Pregnancy & Lactation

                Pregnancy Category: X

                Lactation: excretion in breast milk unknown/not recommended

                Pregnancy Categories

                A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

                B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

                C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

                D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

                X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

                NA: Information not available.

                Previous
                Next:

                Pharmacology

                Mechanism of Action

                Inhibits bacterial urease, decreasing ammonia production

                Does not acidify urine or have direct antibacterial effect

                Pharmacokinetics

                Absorption: Well-absorbed

                Peak Plasma Time: 15 min -1 hr

                Excretion: Urine (55% of oral dose unchanged)

                Previous
                Next:

                Images

                BRAND FORM. UNIT PRICE PILL IMAGE
                Lithostat oral
                -
                250 mg tablet

                Copyright © 2010 First DataBank, Inc.

                Previous
                Next:

                Patient Handout

                A Patient Handout is not currently available for this monograph.
                Previous
                Next:

                Formulary

                FormularyPatient Discounts

                Adding plans allows you to compare formulary status to other drugs in the same class.

                To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

                Adding plans allows you to:

                • View the formulary and any restrictions for each plan.
                • Manage and view all your plans together – even plans in different states.
                • Compare formulary status to other drugs in the same class.
                • Access your plan list on any device – mobile or desktop.

                The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

                Tier Description
                1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
                2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
                3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
                4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                NC NOT COVERED – Drugs that are not covered by the plan.
                Code Definition
                PA Prior Authorization
                Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
                QL Quantity Limits
                Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
                ST Step Therapy
                Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
                OR Other Restrictions
                Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
                Additional Offers
                Email to Patient

                From:

                To:

                The recipient will receive more details and instructions to access this offer.

                By clicking send, you acknowledge that you have permission to email the recipient with this information.

                Email Forms to Patient

                From:

                To:

                The recipient will receive more details and instructions to access this offer.

                By clicking send, you acknowledge that you have permission to email the recipient with this information.

                Previous
                Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.